Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

Agios mulls early FDA filing for sickle cell therapy

 April 1, 2026

Pharmaphorum

Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.

RegulatoryHematologyRead full story

Post navigation

Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout →
← A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com